1. Home
  2. RGCO vs MDWD Comparison

RGCO vs MDWD Comparison

Compare RGCO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RGC Resources Inc.

RGCO

RGC Resources Inc.

N/A

Current Price

$22.74

Market Cap

233.9M

Sector

Utilities

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

N/A

Current Price

$17.49

Market Cap

224.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RGCO
MDWD
Founded
1912
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Oil & Gas Production
Medicinal Chemicals and Botanical Products
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.9M
224.6M
IPO Year
2005
2013

Fundamental Metrics

Financial Performance
Metric
RGCO
MDWD
Price
$22.74
$17.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
8.2K
71.2K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
3.87%
N/A
EPS Growth
11.21
N/A
EPS
0.47
N/A
Revenue
$95,334,212.00
N/A
Revenue This Year
$8.27
$57.63
Revenue Next Year
$3.36
$26.44
P/E Ratio
$47.96
N/A
Revenue Growth
12.63
N/A
52 Week Low
$19.68
$14.14
52 Week High
$23.82
$22.51

Technical Indicators

Market Signals
Indicator
RGCO
MDWD
Relative Strength Index (RSI) 62.21 48.61
Support Level $20.49 $16.71
Resistance Level $23.01 $18.58
Average True Range (ATR) 0.57 0.63
MACD 0.12 -0.01
Stochastic Oscillator 92.89 49.73

Price Performance

Historical Comparison
RGCO
MDWD

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: